HIV-Recreational & Narcotics 4+

Application Description:
This application was developed with funding from the Northeast/Caribbean AIDS Education and Training Center Program and was designed for practicing clinicians to provide information on HIV medications and drug interactions with commonly co-prescribed Opioids, Medication Assisted Treatment, Recreational Substances, and Reversal medications. The four tabs at the bottom of the application include: HIV-Opioid, MAT, Reversal Medication Interactions, HIV-Recreational Drug Interactions, Drug Metabolism, and Common Web Resources. The Common Web Resources tab contains links to external websites and phone numbers for information and national warmlines that provide clinical support with HIV care, substance use, Hepatitis C, and COVID-19.

The data set for the drug interaction output for this application was developed using the Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and other various sources. The application was developed and launched under the direction of VirologyEd Consultants, LLC.

Disclaimer:
The information contained in this application has been developed from various resources, however majority of information is from the DHHS HIV Guidelines referenced below. While the information contained in this has been reviewed, users should be aware that there may be contraindicated or combinations that may lead to adverse events that are not contained here. As with any drug interaction resource, providers are encouraged to consult additional references to verify information prior to making clinical decisions. These guidelines are for informational purposes only and cannot identify medical risks specific to an individual patient or recommend patient treatment. The absence of typographical errors is not guaranteed. These guidelines are not necessarily all-inclusive. Use of these guidelines indicates acknowledgement that neither Northeast/Caribbean AETC, nor the authors will be responsible for any loss or injury, sustained in connection with, or as a result of, the use of these guidelines. Users of this guide should consult other sources before prescribing medications or treatment.

HRSA disclosure:
Funding for this presentation was made possible by TR753197 from the Health Resources and Services Administration’s HIV/AIDS Bureau. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Any trade/brand names for products mentioned during this presentation are for training and identification purposes only.